39. NON-SMALL CELL LUNG CANCER WITH SIMULTANEOUS EGFR AND PIK3CA GENE MUTATIONS: PRELIMINARY TREATMENT RESULTS AT NATIONAL LUNG HOSPITAL FROM 2022 TO 2024
Main Article Content
Abstract
Introduction: Targeted therapy treatment in non-small cell lung cancer patients significantly improves survival and quality of life for patients with EGFR mutations The coexistence of EGFR/PIK3CA mutations is considered a factor affecting the efficacy of EGFR-TKIs treatment in patients with non-small cell lung cancer (NCSLS).
Methods: The cross-sectional descriptive study was conducted on 6 patients with concurrent EGFR and PIK3CA mutations at the National Lung Hospital.
Results: 6/8 patients (75%) had EGFR Del19 mutations, 2/8 patients had L858R mutation. The mean age of the study group was 63.4 years, with 3 male patients (37.5%) and 5 female patients (62.5%). 4/8 patients (50%) had PIK3CA exon 9 mutations, 2/8 patients (25%) had PIK3CA exon 4 mutation. The remaining 2 patients respectively carried PIK3CA exon 2 and exon 20 mutations. The median progression-free survival (PFS) was 10.2 months and overall response rate (ORR) was 62,5%, with 2/8 patients (25%) becoming resistant and treated with second-line chemotherapy and palliative care. There were no serious adverse effects in these patients.
Conclusion: The use of EGFR-TKIs as first-line treatment was effective in this group of EGFR/ PIK3CA co-mutated patients.
Article Details
Keywords
Non-small cell lung cancer (NCSLS), co-mutation, EGFR, PIK3CA, EGFR TKI, initial treatment.
References
Version 3.2022, NCCN Clinical Practice
Guidelines in Oncology, J. Natl. Compr. Cancer
Netw. JNCCN, vol. 20, no. 5, pp. 497–530, May
2022, doi: 10.6004/jnccn.2022.0025.
[2] X. Liu, W. Mei, P. Zhang et al., PIK3CA mutation
as an acquired resistance driver to EGFR-TKIs in non-
small cell lung cancer: Clinical challenges and opportunities,
Pharmacol. Res.,vol. 202, p. 107123, Apr. 2024, doi: 10.1016/j.
phrs.2024.107123.
[3] S.-G. Wu, Y.-L. Chang, C.-J. Yu et al., The Role
of PIK3CA Mutations among Lung Adenocarcinoma
Patients with Primary and Acquired Resistance to
EGFR Tyrosine Kinase Inhibition, Sci.Rep., vol. 6, p. 35249,
Oct. 2016, doi: 10.1038/srep35249.
[4] M. Scheffler et al., PIK3CA mutations in nonsmall cell
lung cancer (NSCLC): Genetic heterogeneity, prognostic
impact and incidence of prior malignancies, Oncotarget,
vol. 6, no. 2, pp. 1315–1326, Jan. 2015, doi: 10.18632/
oncotarget.2834.
[5] C. Jing et al., Next-generation sequencing-based
detection of EGFR, KRAS, BRAF, NRAS, PIK-
3CA, Her-2 and TP53 mutations in patients with
non-small cell lung cancer, Mol. Med. Rep.,
vol. 18, no. 2, pp. 2191–2197, Aug. 2018, doi:
10.3892/mmr.2018.9210.
[6] Liang N., Liu Y., Liu L. et al., Co-mutation of
PIK3CA and Other Oncogenes in Patients with
Non-small Cell Lung Cancer, 协和医学杂
志, vol. 6, no. 3, pp. 186–190, May 2015, doi:
10.3969/j.issn.1674-9081.2015.03.005.
[7] “Activating mutations in EGFR and PI3K promote
ATF4 induction for NSCLC cell survival during amino acid
deprivation - PubMed.”Accessed: Apr. 01, 2024. [Online].
Available: Https://pubmed.ncbi.nlm.nih.gov/37025861/
[8] J.-Y. Chen et al., Predictive value of K-ras and
PIK3CA in non-small cell lung cancer patients
treated with EGFR-TKIs: A systemic review
and meta-analysis, Cancer Biol. Med., vol. 12,
no. 2, pp. 126–139, Jun. 2015, doi: 10.7497/j.
issn.2095-3941.2015.0021.